FHI
$55.67-0.13 (-0.23%)
Federated Hermes, Inc.
Recent News
Two Biotech Stocks Hover Near Highs; Natural Gas And Finance Names Show Resilience
Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market.
Federated Hermes (FHI) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Federated Hermes (FHI) have what it takes? Let's find out.
How The Federated Hermes (FHI) Story Is Shifting With New Targets And Flow Signals
Federated Hermes is back in focus after analysts adjusted their price targets, with one fair value estimate moving to US$55.57 and another high end target shifting to US$60 from US$55. These moves reflect recent research that mixes cautious tweaks, such as JPMorgan’s US$1 cut, with more constructive revisions tied to early reads on asset manager flows. As you read on, you will see how to interpret these shifts and track the evolving narrative around the stock. Stay updated as the Fair Value...
2 Reasons to Like FHI and 1 to Stay Skeptical
Federated Hermes trades at $55.62 and has moved in lockstep with the market. Its shares have returned 5.4% over the last six months while the S&P 500 has gained 2.3%.
1 Surging Stock to Consider Right Now and 2 We Avoid
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.